Huynh et al. reported that HAPLN1 is produced by bone marrow stromal cells in multiple myeloma (MM) patients and it can activate an atypical bortezomib-resistant NF-κB pathway in MM cells. This evidence concerns the gene NFKB1 and Miyoshi myopathy.